New hope for hodgkin lymphoma patients who Can't get transplants

NCT ID NCT06393361

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of drugs (Chidamide, Decitabine, and an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to treatment, and who cannot or choose not to have a stem cell transplant. The goal is to see if this combo helps keep the cancer from growing for at least a year. About 100 adults aged 18 to 75 will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INELIGIBLE OR REFUSED TRANSPLANT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital

    RECRUITING

    Beijing, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••